Skip to content
Study details
Enrolling now

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Emory University
NCT IDNCT05244239ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

22

Study length

about 5 years

Ages

18+

Locations

3 sites in GA

What this study is about

This trial is testing if it is safe to use palliative radiotherapy and lurbinectedin at the same time to treat small cell lung cancer that has spread outside of the chest. It aims to determine if this combination treatment works better than either one alone or causes more side effects.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Palliative Radiation Therapy
  • 2.Take Lurbinectedin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lurbinectedin

Drug routes

injection, intravenous

Endpoints

Primary: Incidence of adverse events of palliative radio therapy (RT) with lurbinectedin

Secondary: Overall survival (OS), Pain response rates, Patient-reported toxicity, Progression free survival (PFS), Response rate

Procedures

radiation